Micro X (ASX:MX1) - Managing Director, Peter Rowland
Managing Director, Peter Rowland
Source: Micro-X/ Twitter
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Hi-tech company Micro-X (MX1) has signed a project agreement with the Australian Stroke Alliance (ASA)
  • The agreement will see Micro-X become the technology partner for the development of lightweight stroke diagnostic imaging technology
  • ASA was granted $40 million from the Australian Government for its ‘Stroke Golden Hour’ project proposal to transform pre-hospital stroke care
  • The newly signed agreement will unlock $8 million of funding from the $40 million grant
  • Micro-X closed up 1.72 per cent at 29.5 cents per share

Micro-X (MX1) has signed a project agreement with the Australian Stroke Alliance (ASA).

The healthcare company has started developing a small CT brain scanner that can be fitted in ambulances and emergency aircraft. If successful, this device will allow paramedics and retrieval teams to diagnose and then start treating stroke patients in the ‘golden hour’ – the first hour after a stroke.

ASA was granted $40 million from the Australian Government for its Stroke Golden Hour project proposal to transform pre-hospital stroke care.

The organisation selected Micro-X as its technology partner due to its unique electronic x-ray tube capabilities.

The newly signed agreement will unlock $8 million of funding from the $40 million grant and will be used to development of this scanner for patient imaging trials in 2023.

Managing Director Peter Rowland is pleased with this new contract.

“We are delighted to execute this contract with the Australian Stoke Alliance and are excited that the mobility of our technology, developed here in South Australia, will act as a game changer to pre-hospital stroke care, particularly in
remote and rural areas,” he said.

“The proliferation of stroke imaging in air and land ambulances will make a huge impact on stroke survival and recovery rates. We’ve already begun preliminary work which has delivered promising results and look forward to working closely with our partners at the Melbourne Brain Centre, ASA, Johns Hopkins and Fujifilm to turn this concept into a reality.”

This year, strokes will affect more than 15 million people worldwide. Of these five million will not survive, while another five million will be permanently disabled.

In Australia about 38,000 people have a stroke each year, which equates to about 100 a day.

Micro-X closed up 1.72 per cent at 29.5 cents per share.

mx1 by the numbers
More From The Market Online
London

With osteo Phase 3 trial at 50% recruitment, Paradigm Bio inks partnership with University of London

Paradigm Biopharma (ASX:PAR) has this week hit two big items out the park: first of all, hitting 50% recruitment

Emyira ramps up national growth strategy with NSW recruitment campaign

Emyira has initiated a significant growth program with a targeted clinical workforce recruitment campaign underway in…

Investors will get interim results from Paradigm’s Phase III study in Q3 of this year

Paradigm Biopharma has officially passed a milestone that gives investors in the company a 'fast-track' path…

Radiopharm Theranostics doses first patient in prostate cancer clinical study

Radiopharm Theranostics has dosed the first patient in its phase one clinical trial of a potential…